vs
Side-by-side financial comparison of DYNEX CAPITAL INC (DX) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $43.5M, roughly 1.6× DYNEX CAPITAL INC). On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 531.3%).
Dynex Capital Inc. is a publicly traded real estate investment trust headquartered in the United States. It specializes in investing in and managing a diversified portfolio of mortgage-backed securities, residential and commercial mortgage loans, and other mortgage-related assets. It delivers consistent returns to shareholders via regular dividends and long-term capital growth.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
DX vs VRDN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $43.5M | $70.6M |
| Net Profit | — | $-34.6M |
| Gross Margin | — | — |
| Operating Margin | — | -56.7% |
| Net Margin | — | -49.0% |
| Revenue YoY | 531.3% | 81958.1% |
| Net Profit YoY | — | 54.9% |
| EPS (diluted) | $1.59 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $43.5M | — | ||
| Q3 25 | $30.6M | $70.6M | ||
| Q2 25 | $23.1M | — | ||
| Q1 25 | $17.1M | — | ||
| Q1 24 | $-3.2M | — | ||
| Q4 22 | $6.2M | — | ||
| Q3 22 | $7.1M | — | ||
| Q2 22 | $14.1M | — |
| Q4 25 | — | — | ||
| Q3 25 | $150.4M | $-34.6M | ||
| Q2 25 | $-13.6M | — | ||
| Q1 25 | $-3.1M | — | ||
| Q1 24 | $40.1M | — | ||
| Q4 22 | $43.3M | — | ||
| Q3 22 | $-46.7M | — | ||
| Q2 22 | $29.3M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -56.7% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q1 24 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 491.3% | -49.0% | ||
| Q2 25 | -58.8% | — | ||
| Q1 25 | -18.0% | — | ||
| Q1 24 | -1256.8% | — | ||
| Q4 22 | 697.2% | — | ||
| Q3 22 | -655.3% | — | ||
| Q2 22 | 208.5% | — |
| Q4 25 | $1.59 | — | ||
| Q3 25 | $1.08 | — | ||
| Q2 25 | $-0.14 | — | ||
| Q1 25 | $-0.06 | — | ||
| Q1 24 | $0.64 | — | ||
| Q4 22 | $0.44 | — | ||
| Q3 22 | $-1.07 | — | ||
| Q2 22 | $0.69 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $531.0M | $490.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.5B | $503.0M |
| Total Assets | $17.3B | $577.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $531.0M | — | ||
| Q3 25 | $491.0M | $490.9M | ||
| Q2 25 | $387.5M | — | ||
| Q1 25 | $327.4M | — | ||
| Q1 24 | $295.7M | — | ||
| Q4 22 | $332.0M | — | ||
| Q3 22 | $260.4M | — | ||
| Q2 22 | $325.7M | — |
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.0B | $503.0M | ||
| Q2 25 | $1.6B | — | ||
| Q1 25 | $1.4B | — | ||
| Q1 24 | $958.5M | — | ||
| Q4 22 | $901.3M | — | ||
| Q3 22 | $771.3M | — | ||
| Q2 22 | $842.4M | — |
| Q4 25 | $17.3B | — | ||
| Q3 25 | $14.2B | $577.1M | ||
| Q2 25 | $11.3B | — | ||
| Q1 25 | $9.0B | — | ||
| Q1 24 | $6.3B | — | ||
| Q4 22 | $3.6B | — | ||
| Q3 22 | $4.0B | — | ||
| Q2 22 | $3.2B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $120.8M | $-84.6M |
| Free Cash FlowOCF − Capex | — | $-84.7M |
| FCF MarginFCF / Revenue | — | -120.1% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $120.8M | — | ||
| Q3 25 | $68.3M | $-84.6M | ||
| Q2 25 | $31.9M | — | ||
| Q1 25 | $6.4M | — | ||
| Q1 24 | $-17.1M | — | ||
| Q4 22 | $30.1M | — | ||
| Q3 22 | $25.5M | — | ||
| Q2 22 | $36.2M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $-84.7M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q1 24 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -120.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q1 24 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q1 24 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.45× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q1 24 | -0.43× | — | ||
| Q4 22 | 0.69× | — | ||
| Q3 22 | — | — | ||
| Q2 22 | 1.23× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
